EU Data

Strategies include engineering T cells to release cytokines that recruit and activate other immune cells, as well as targeting regulatory cells within the TME that suppress immune responses. Patents in this area include U.S. Patent No. 9,393,308, which covers methods for modifying the TME to enhance anti-tumor immunity, and U.S. Patent No. 10,024,729, which uses engineered immune cells to alter the TME. 3.4. Combining Cell Therapies with Other Methods If cell therapies are s, such as chemotherapy, radiation, and immune checkpoint inhibitors, there is a potential for synergistic effects.


For example, by combining CAR-T cells togo b2b leads with checkpoint inhibitors, T-cell activity can be enhanced and tumor resistance mechanisms can be overcome. Similarly, radiation therapy can increase the expression of tumor antigens, making cancer cells more recognizable to engineered T cells. Relevant patents include U.S. Patent No. 9,850,302, which covers combination therapies involving CAR-T cells and checkpoint inhibitors, and U.S. Patent No. 10,016,603, which relates to combining cell therapies with radiation treatment. 3.5. Personalized Cell Therapies Personalizing cell therapies based on an individual's genetic and molecular cancer profile is a growing trend.